- Home
- ABOS vs SGMT Comparison
ABOS vs SGMT Comparison
Compare ABOS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABOS | SGMT |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.9M | 169.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ABOS | SGMT |
|---|---|---|
| Price | $2.24 | $8.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $8.00 | ★ $26.13 |
| AVG Volume (30 Days) | 353.9K | ★ 992.5K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.19 | $4.50 |
| 52 Week High | $3.60 | $10.06 |
Technical Indicators
Market Signals| Indicator | ABOS | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 47.48 | 66.46 |
| Support Level | $2.13 | $6.95 |
| Resistance Level | $2.43 | $8.84 |
| Average True Range (ATR) | 0.12 | 0.50 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 53.33 | 94.81 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.